Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 13;12(1):25.
doi: 10.1186/s13741-023-00315-1.

Review of cancer therapies for the perioperative physician

Anahita Dabo-Trubelja  1 , Vijaya Gottumukkala  2
Affiliations
Review

Review of cancer therapies for the perioperative physician

Anahita Dabo-Trubelja et al. Perioper Med (Lond). .

Abstract

Advances in cancer treatments over the past decades combining chemotherapy with novel technologies in immunotherapies, radiation therapies, and interventional radiology have prolonged life expectancy. Patients have more options for treatments of their primary or metastatic diseases. Increased procedural techniques amid an aging population with multiple comorbidities present risks and challenges in the perioperative period.Chemotherapy remains the mainstay of cancer treatment, can be given intraoperatively, and is combined with other treatment modalities. Immunotherapy is particular to cancer cells while being less toxic to healthy cells. Cancer vaccines stimulate the immune system to stop disease progression. Oncolytic viruses enhance the immune system's cytotoxic effect and show promise to halt metastatic disease progression if present in the perioperative period. Novel techniques in radiation therapy combined with traditional treatments show enhanced survival. This review focuses on current cancer treatments encountered in the perioperative period.

Keywords: Anesthesiology; Cancer vaccines; Chemotherapy; Immunotherapy; Interventional radiology therapy; Perioperative physician; Radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Aakre BM, Efem RI, Wilson GA, Kor DJ, Eisenach JH. Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc. 2014;89:181–189. doi: 10.1016/j.mayocp.2013.11.007. - DOI - PMC - PubMed
    1. Abuosa AM, Elshiekh AH, Qureshi K, Abrar MB, Kholeif MA, Kinsara AJ, et al. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart J. 2018;70(Suppl 3):S96–100. doi: 10.1016/j.ihj.2018.06.011. - DOI - PMC - PubMed
    1. Adam R, Wicherts DA, de Haas RJ, Ciancio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–1835. doi: 10.1200/JCO.2008.19.9273. - DOI - PubMed
    1. Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS. 2016;124:896–904. doi: 10.1111/apm.12576. - DOI - PubMed
    1. Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007;3:213–224. doi: 10.2147/tcrm.2007.3.2.213. - DOI - PMC - PubMed

LinkOut - more resources